Blood Tests May Help Predict Rejection in Pig Islet Transplants for Type 1 Diabetes

Islet transplantation—transferring insulin-producing cells from one person or animal to another—is a potential treatment strategy for Type 1 diabetes. However, the immune system often attacks and destroys these foreign cells, a process called rejection. Even when doctors use powerful immunosuppressive drugs to prevent rejection, many transplants fail within months or years.

Finding better ways to predict and prevent rejection could extend the lifespan of transplants and improve outcomes for recipients.

Researchers transplanted islets from genetically modified pigs into ten diabetic baboons. The pig islets were engineered to express human immune-protective proteins, reducing the mismatch between donor and recipient. All recipients received anti-rejection medications including anti-CD2 therapy, anti-CD154, and Belatacept. Seven animals also received full-dose Tacrolimus; three received reduced or no Tacrolimus.

The key innovation was using flow cytometry—a technique that analyzes individual cells in a blood sample—to continuously monitor the recipient's immune activity. Researchers tracked T cells, leukocytes, and other immune markers throughout the study.

All ten baboons produced porcine C-peptide, a marker that the transplanted islets were alive and secreting insulin. However, survival patterns diverged sharply. The seven animals on full-dose Tacrolimus maintained working islet grafts for as long as 675 days. The three on reduced or no Tacrolimus experienced acute rejection within two months.

Flow cytometry provided actionable information: animals that later had long-term graft survival showed much greater T-cell suppression in the first month (averaging 36.47% unoccupied CD2 on T cells) compared to those that rejected their grafts (averaging 176.28%). In other words, the blood test detected differences in immune control that predicted clinical outcomes.

The test was also practical. It required only 50 microliters of blood—about one-tenth of a standard blood draw—and took roughly 50 minutes instead of 150 minutes to process, while generating cell counts equivalent to a full blood count.

This research is early-stage: it was conducted in baboons, not humans. However, the findings suggest that routine immune monitoring via flow cytometry could help doctors detect rejection risk before grafts fail. Instead of waiting for clinical signs like high blood glucose levels, physicians might use T-cell suppression patterns to adjust immunosuppressive therapy in real time.

For people with Type 1 diabetes considering islet transplantation, better monitoring tools could mean longer-lasting grafts and more stable blood sugar control. The next steps will involve testing this monitoring approach in human transplant recipients and determining how to translate immune markers into clinical decisions.

Source: Xenotransplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.